观察达格列净对血糖控制不达标的超重和肥胖2型糖尿病患者血糖控制效果及BMI和肾功能的影响

Observation on the Effect of Dapagliflozin on Blood Glucose Control,BMI and Renal Function in Overweight and Obese Type 2 Diabetic Patients Whose Blood Glucose Control is not up to Standard

目的 观察达格列净对血糖控制不达标的超重和肥胖2型糖尿病患者血糖控制效果及体质指数(BMI)和肾功能的影响。方法 选取2020年6月—2021年6月期间经中国药科大学第一附属医院确诊的68例2型糖尿病患者为研究对象,按照随机数表法分两组,均34例,对照组予以常规降糖治疗,研究组在对照组基础上加用达格列净治疗。治疗3个月后进行效果评估。结果 经过3个月的治疗,研究组空腹血糖水平为(6.53±1.38)mmol/L、餐后2 h血糖水平(10.89±2.01)mmol/L及糖化血红蛋白(7.01±0.96)%较对照组低,差异有统计学意义(t=3.685、2.458、2.851,P<0.05);研究组BMI水平(25.23±1.68)kg/m^(2)较对照组的(25.99±1.32)kg/m^(2)低,差异有统计学意义(t=2.074,P<0.05);肥胖发生率26.47%,低于对照组50.00%,差异有统计学意义(χ^(2)=3.985,P<0.05);研究组Scr及UACR水平分别为(70.82±16.89)μmol/L、(15.86±5.58)mg/g均较对照组低,差异有统计学意义(t=2.330、2.663,P<0.05);研究组每日胰岛素用量(35.15±4.28)U/d较对照组的(41.08±4.73)U/d低,差异有统计学意义(t=5.421,P<0.05)。结论 达格列净用于血糖控制不佳的超重或肥胖2型糖尿病患者可有效提高血糖控制效果,减少胰岛素用量,促进BMI下降,同时还能对肾功能起到保护作用。

Objective To observe the effect of dapagliflozin on blood glucose control,BMI and renal function in overweight and obese patients with type 2 diabetes mellitus whose blood glucose control is not up to standard.Methods A total of 68 patients with type 2 diabetes diagnosed inthe First Affiliated Hospital of China Pharmaceutical University from June 2020 to June 2021 were selected as the research object and divided into 2 groups according to the random number table method,each with 34 cases.The control group was given conventional hypoglycemic treatment,and the study group was given dapagliflozin treatment on the basis of the control group.The effect was evaluated after 3months of treatment.Results After 3 months of treatment,the fasting blood glucose level of the study group was(6.53±1.38) mmol/L,the 2 h postprandial blood glucose level was(10.89±2.01) mmol/L and the glycosylated hemoglobin(7.01±0.96)% were lower than that of the control group,the difference was statistically significant(t=3.685,2.458,2.851,P<0.05);the BMI level of the study group(25.23±1.68) kg/m^(2) was lower than that of the control group(25.99±1.32) kg/m^(2),and the difference was statistically significant(t=2.074,P<0.05);the incidence of obesity was 26.47%,which was lower than that of the control group 50.00%,and the difference was statistically significant(χ^(2)=3.985,P<0.05);the levels of Scr and UACR in the study group were(70.82±16.89) μmol/L and(15.86±5.58) mg/g,respectively,which were lower than those in the control group,the difference was statistically significant(t = 2.330,2.663,P<0.05);the daily insulin dosage of the study group(35.15±4.28) U/d was lower than that of the control group(41.08±4.73) U/d,and the difference was statistically significant(t=5.421,P<0.05).Conclusion Dapagliflozin for overweight or obese patients with type 2 diabetes mellitus with poor blood glucose control can effectively improve blood glucose control effect,reduce insulin dosage,and promote BMI decrease.It can also protect kidney function.